Published Date: 21-Feb-2023
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Real World Evidence Solutions Market size is expected to reach $65.1 billion by 2028, rising at a market growth of 8.0% CAGR during the forecast period.
The Data Set segment is showcasing a CAGR of 7.3% during (2022 - 2028). The clinical settings, insurance claims, pharmacy, and patient-powered data segments make up the data sets segment. The segment is predicted to rise as a result of the increase in data volume produced in healthcare institutions and increased interest in further epidemiological insights.
The Oncology segment acquired maximum revenue share in the Global Real World Evidence Solutions Market by Therapeutic Area in 2021 thereby, achieving a market value of $18.4 billion by 2028. Oncologists have employed RWE to enhance various clinical decision-making processes, including patient profiling, disease diagnosis, optimal dosing, comprehension of therapy patterns, and more assured adverse events (AEs) management. Healthcare professionals (HCPs), patient advocates, regulators, and payers are among the stakeholders in the oncology care continuum expected to gain from RWE.
The Healthcare Providers segment has shown the growth rate of 8.2% during (2022 - 2028). The growing awareness among payers of the significance of medical drug/device safety & their harmful effects and the advantageous reimbursement situation are responsible for the segment's growth. This is especially true for instances in developed nations.
The Drug Development & Approvals segment is leading the Global Real World Evidence Solutions Market by Application in 2021 thereby, achieving a market value of $19.2 billion by 2028. RWE solutions services enable pharmaceutical firms, healthcare organizations, and payers to manage operations effectively and quicken the development and approval of new drugs. This promotes market expansion. Due to the urgency of creating vaccines and medications during the COVID-19 pandemic, top healthcare organizations wanted to expand the usage of RWE beyond its conventional safety-related applications.
The North America market dominated the Global Real World Evidence Solutions Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $26.9 billion by 2028.The Europe market is exhibiting a CAGR of 8.2% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 9% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/real-world-evidence-solutions-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.
By Therapeutic Area
Unique Offerings from KBV Research
North America Real World Evidence Solutions Market size & Opportunities 2022-2028
Europe Real World Evidence Solutions Market & Growth Forecast 2022-2028
Asia Pacific Real World Evidence Solutions Market Share & Industry Outlook to 2028
LAMEA Real World Evidence Solutions Market Growth, Trends & Forecasts 2022-2028